title: Correction to Lancet Oncol 2015; 16: 499-508. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
authors.forename: J
authors.initials: J
authors.lastname: Tabernero
authors.forename: Y
authors.initials: Y
authors.lastname: Takayuki
authors.forename: A L
authors.initials: AL
authors.lastname: Cohn